Here are the DEF 14A proxy statements from GP-Act III Acquisition Corp. Warrants (GPATW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow GPATW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GPATW filings page.
GP-Act III Acquisition Corp. (GPAT) is asking shareholders to extend its deadline to complete a business combination from November 13, 2026, to May 8, 2027, and to extend the Trust Account’s liquidation date to May 8, 2027. Both amendments must be approved for the extension to take effect. A separate adjournment proposal would allow more time to solicit votes if needed; the company is not asking shareholders to vote on a business combination now.
The proposed extension would give GPAT more time to negotiate a potential share exchange with an aerospace and logistics technology company. The parties signed a non-binding term sheet on July 10, 2026, and negotiations are at an advanced stage, but there is no assurance they will sign a definitive agreement or complete the transaction. The Trust Account held $99,392,076.68 as of October 26, 2026, and GPAT anticipates an approximately $11.07 per-share redemption price at the meeting. Redemptions could leave only a small fraction of that balance, potentially affecting funds available for a transaction. If the amendments fail and GPAT does not complete a business combination by November 13, 2026, it would wind up and redeem public shares; warrants would expire worthless.
GP-Act III Acquisition Corp. is asking shareholders to extend its deadline to complete a business combination from May 13, 2026 to November 13, 2026. The meeting will also vote on amending the trust agreement and a possible adjournment to gather more votes.
Holders of Class A public shares can redeem shares in connection with the extension for cash equal to their pro rata share of the trust account. Based on $311,838,315.48 in the trust as of March 30, 2026, the estimated redemption price is about $10.84 per share.
If the extension or trust amendment is not approved, or if negotiations on the potential business combination end before the meeting, the SPAC plans to redeem all public shares and liquidate, with its warrants expiring worthless and founder shares receiving no trust proceeds.